Lakefront Biotherapeutics (GLPGF) Cash from Investing Activities Growth (3y) (2018 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Cash from Investing Activities Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | -39.19% |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | -177.73% |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 46.78% |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 66.14% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | -44.69% |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | -246.81% |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -72.08% |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 30.69% |
| Dec 31, 2025 | 27.37% |
| Mar 31, 2025 | 27.75% |
| Jun 30, 2024 | -31.32% |
| Mar 31, 2024 | -62.33% |
| Mar 31, 2023 | -32.04% |
| Dec 31, 2022 | 32.69% |
| Mar 31, 2022 | -547.33% |
| Jun 30, 2021 | 341.12% |
| Mar 31, 2021 | 585.81% |
| Jun 30, 2020 | -27.01% |
| Mar 31, 2020 | 459.59% |
| Dec 31, 2019 | -709.08% |
| Jun 30, 2019 | -38.36% |
| Mar 31, 2019 | -49.40% |
| Dec 31, 2018 | -56.82% |